ClinicalTrials.gg
Not yet recruitingNCT07095309NeoART-MUpdated Jul 31, 2025

Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer

A Phase 2 interventional study of Artesunate and Artesunate matching Placebo in Stage II/III Colon Cancer and Bowel Cancer, sponsored by Metanoic Health Ltd.. Not yet recruiting at 6 sites in Malaysia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Metanoic Health Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

TThis study evaluates the safety and effectiveness of pre-operative artesunate, given orally once a day for 14 days prior to surgery, in patients with Stage II/III colorectal cancer.

Artesunate is an established antimalarial drug with an excellent safety profile. It is well tolerated, affordable, and widely available. Several laboratory studies and one small pilot clinical study in patients with colorectal cancer have shown that artesunate can reduce the proliferation and growth of cancer cells.

One hundred patients diagnosed with Stage II/III operable colorectal cancer will be randomly allocated to receive oral artesunate 200 mg daily or a matching placebo for 14 days prior to surgery. Patients will then be followed closely for 5 years to determine whether pre-operative artesunate reduces the risk of cancer recurrence after surgery.

Read the detailed description

Artesunate is an established antimalarial drug belonging to the artemisinin class of drugs, has an excellent safety profile, is well tolerated and affordable. In last two decades, artemisinins have shown potent and broad anticancer properties in a range of cell lines and animal models, supporting the hypothesis that artemisinins have the potential to be an effective anti-cancer therapy. Multiple potential mechanisms of action include anti-proliferative effects through cell-cycle disruption, reactive oxygen species (ROS) -induced DNA damage, induction of apoptosis, anti-angiogenesis, immunomodulation and induced radiosensitivity.

Despite a multi-modality treatment approach to colorectal cancer, 5 year overall survival does not currently exceed 60%. Neoadjuvant pre-operative therapy may be more effective at eradicating micrometastases compared to adjuvant therapy delivered following the delay and immunological stress of surgery. However current neoadjuvant chemotherapy regimens are often associated with significant side effects and may result in a delay in surgery whilst patients recover. A well tolerated, affordable, novel anticancer agent that could be given to patients whilst they wait for surgery, without causing a surgical delay due to treatment related toxicity, would have a significant clinical impact on patient care.

The NeoART trial is a phase II multicentre randomised, double blind, placebo controlled trial (RCT) for patients undergoing primary surgery for Stage II/III colorectal cancers. Patients are randomised (1:1 ratio) to receive either a two week course of neoadjuvant artesunate 200mg once daily or matching placebo. Both patients and health care professionals are blinded to treatment allocation arm to minimise outcome-reporting bias. The primary endpoint of the trial is recurrence free survival two years after surgery. Secondary endpoints include 2 and 5 year overall survival, treatment related toxicity, tolerability and patient quality of life. A translational sub-study looking at predictive and prognostic biomarkers is also planned.

02

Conditions studied

  • Stage II/III Colon Cancer
  • Bowel Cancer

Browse trials for

Keywords

  • artesunate
  • colorectal
  • drug repurposing
  • antimalarial
03

In context

Intestinal Neoplasms

110 studies on the registry are indexed under Intestinal Neoplasms; 25 are open to participants now.

This study's planned enrollment of 120 is close to the median of 120 across 71 interventional studies indexed under Intestinal Neoplasms.

Browse Intestinal Neoplasms studies →

Lead sponsor

Metanoic Health Ltd. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 or over
  • proven single primary site colorectal adenocarcinoma or high grade dysplasia plus unequivocal radiological evidence of invasive cancer
  • Stage II/III colorectal cancer planned for surgical resection and no clinical indication for preoperative chemotherapy/chemoradiation therapy
  • 0,1 or 2
  • Adequate full blood count: White Cell Count (WCC) >3.0 x 109 /l; >100 x 109/l; (Hb) >80g/L
  • Adequate renal function : >30ml/min by formula.
  • Adequate hepatobiliary function : Total \< 3 x Upper limit norm
  • Female participants of must have a negative pregnancy test \<72 hours prior to initiating study intervention and agree to avoid pregnancy using adequate, medically approved precautions for up to 6 weeks after the last dose of study treatment interventions.
  • Male participants with a partner of childbearing potential must agree to use adequate, medically approved contraceptive precautions during and for up to 6 weeks after the last dose of the study treatment intervention.
  • Patient able and willing to provide written, for the study.

Exclusion criteria

Exclusion Criteria:

  • to use of artesunate due to
  • Pregnancy or lactation
  • Male or female participants unwilling to use an effective method of (either hormonal in the form of the contraceptive pill or barrier method of birth control accompanied by the use of a proprietary spermicidal foam/gel or film) ; or agreement of true abstinence from time consent is signed until 6 weeks after the last dose of study treatment intervention (i.e. withdrawal, calendar, ovulation, symptothermal and post ovulation are not acceptable methods)
  • History of hearing or balance problems
  • History of
  • Patient weight \< 52 kg or > 110 kg
  • Other planned intervention, apart from standard of care
  • Any other malignant disease diagnosis within the preceding 2 years with the exception of non-melanomatous skin cancer and carcinoma in situ
  • Lactose intolerance
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Artesuante

    Artesunate 200mg oral tablets once daily for 14 days.

    Drug: Artesunate

  • Placebo comparator
    Artesunate matching placebo

    Matching placebo oral tablets once daily for 14 days.

    Drug: Artesunate matching Placebo

Interventions

  • Artesunate 200mg PO OD for 14 days prior to colorectal resection surgery

  • DrugArtesunate matching Placebo

    Matched placebo PO OD for 14 days prior to colorectal resection surgery

06

What researchers measure

Primary outcomes

  1. Recurrence-Free Survival (RFS) at 2 Years Post-Randomisation Assessed by Radiological and Clinical Evaluation

    RFS is defined as the time from randomisation to the first documented recurrence of colorectal cancer (local or distant) or death from any cause, whichever occurs first. Recurrence will be assessed using standard CT scans of the chest, abdomen, and pelvis, clinical examination and measuring carcinoembryonic antigen (CEA). Confirmation of recurrence may include histological evidence where clinically indicated. Unit of Measure: Months

    Time frame: 2 years following study randomisation.

Secondary outcomes

  1. Recurrence-Free Survival at 5 Years Post-Randomisation Assessed by Radiological and Clinical Evaluation

    RFS is defined as the time from randomisation to the first documented recurrence of colorectal cancer (local or distant) or death from any cause, whichever occurs first. Recurrence will be assessed using standard CT scans of the chest, abdomen, and pelvis, clinical examination and CEA . Histological confirmation of recurrence will be obtained where clinically indicated. Unit of Measure: Months

    Time frame: 5 years from study randomisation

  2. Overall Survival (OS) at 2 and 5 Years Post-Randomisation

    Survival status will be determined through clinical follow-up, hospital records, and national death registries where available. Unit of Measure: Months

    Time frame: 2 years and 5 years following study randomisation.

  3. Colon Cancer-Specific Mortality at 2 and 5 Years Post-Randomisation

    Time frame: 2 years and 5 years following study randomisation.

  4. Incidence of Artesunate-Related Toxicity Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    The number of participants experiencing adverse events considered related to artesunate will be recorded and graded using the CTCAE. Unit of Measure: Number of participants with at least one artesunate-related adverse event, by CTCAE grade.

    Time frame: Assessment at Day 7 following initiation of study intervention (artesunate or matching placebo).

  5. Incidence of Artesunate-Related Toxicity Assessed by Common Terminology CTCAE v5.0

    The number of participants experiencing adverse events considered related to artesunate will be recorded and graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Causality will be assessed by the site investigator and confirmed by the clinical trial safety team. Adverse events will be coded and reported by type and severity.

    Time frame: Assessment at Day 14 following initiation of study intervention (artesunate or matching placebo).

  6. Incidence of Artesunate-Related Toxicity Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    The number of participants experiencing adverse events considered related to artesunate will be recorded and graded using the CTCAE. Causality will be assessed by the site investigator and confirmed by the clinical trial safety team. Adverse events will be coded and reported by type and severity. Unit of Measure: Number of participants with at least one artesunate-related adverse event, by CTCAE grade.

    Time frame: Assessment at Day 42 following initiation of study intervention (artesunate or matching placebo).

  7. Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    The number and proportion of participants experiencing any adverse events (AEs), regardless of causality, will be recorded and graded using the CTCAE. Unit of Measure: Number of participants with at least one adverse event, categorised by CTCAE grade.

    Time frame: Assessment at Day 7 following administration of study intervention (artesunate or matching placebo).

  8. Incidence Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Day 14

    The number and proportion of participants experiencing any adverse events (AEs), regardless of causality, will be recorded and graded using the CTCAE. Unit of Measure: Number of participants with at least one adverse event, categorised by CTCAE grade.

    Time frame: Assessment at Day 14 following study intervention

  9. Incidence of adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    The number and proportion of participants experiencing any adverse events (AEs), regardless of causality, will be recorded and graded using the CTCAE. Unit of Measure: Number of participants with at least one adverse event, categorised by CTCAE grade.

    Time frame: Assessment at Day 42 following study intervention

  10. Pathological assessment of tumour regression post intervention

    Tumour regression will be assessed by histopathological examination of the surgical resection specimen. The assessment will include: * Degree of tumour regression in the primary tumour bed * Presence of tumour involvement at the resection margins * Evidence of tumour invasion into the serosa (pT4a) and lymph node involvement (number and proportion of positive lymph nodes). * Histopathological evaluation Unit of Measure: Number and proportion of participants with positive lymph nodes, serosal involvement, and positive resection margins.

    Time frame: Post surgical pathology review (following Day 14 of study intervention)

  11. Patient-Reported Quality of Life (QoL) Assessed by Validated Questionnaires at Baseline

    Quality of life will be assessed using validated, self-administered questionnaires: 1. EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30) 2. EORTC QLQ-CR29 (Colorectal Cancer-Specific Module) These instruments evaluate global health status/QoL, functional scales (physical, role, emotional, cognitive, social), and symptom scales. Scores for each scale range from 0 to 100. For functional and global health status scales, higher scores indicate better QoL. For symptom scales, higher scores indicate worse symptoms. Unit of Measure: Mean scores for each scale/domain of the EORTC QLQ-C30 and QLQ-CR29 questionnaires.

    Time frame: Assessment at Day 1 of study intervention (baseline assessment)

  12. Patient-Reported Quality of Life (QoL) Assessed by Validated Questionnaires

    Quality of life will be assessed using validated, self-administered questionnaires: 1. EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30) 2. EORTC QLQ-CR29 (Colorectal Cancer-Specific Module) These instruments evaluate global health status/QoL, functional scales (physical, role, emotional, cognitive, social), and symptom scales. Scores for each scale range from 0 to 100. For functional and global health status scales, higher scores indicate better QoL. For symptom scales, higher scores indicate worse symptoms. Unit of Measure: Mean scores for each scale/domain of the EORTC QLQ-C30 and QLQ-CR29 questionnaires.

    Time frame: Assessment at Day 7 of study intervention

  13. Patient-Reported Quality of Life (QoL) Assessed by Validated Questionnaires post intervention

    Quality of life will be assessed using validated, self-administered questionnaires: 1. EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30) 2. EORTC QLQ-CR29 (Colorectal Cancer-Specific Module) These instruments evaluate global health status/QoL, functional scales (physical, role, emotional, cognitive, social), and symptom scales. Scores for each scale range from 0 to 100. For functional and global health status scales, higher scores indicate better QoL. For symptom scales, higher scores indicate worse symptoms. Unit of Measure: Mean scores for each scale/domain of the EORTC QLQ-C30 and QLQ-CR29 questionnaires.

    Time frame: Assessment at Day 14 of study intervention

  14. Incidence of Surgery-Related Adverse Events Assessed by CTCAE v5.0

    The number and proportion of participants experiencing surgery-related adverse events (AEs) will be recorded. Events will be graded using the CTCAE version 5.0, with severity classified from Grade 1 (mild) to Grade 5 (death related to AE). Events of interest include, but are not limited to, surgical site infection, anastomotic leak, wound dehiscence, postoperative bleeding, and thromboembolic events. Unit of Measure: Number of participants with at least one surgery-related AE, categorised by CTCAE grade.

    Time frame: From time of surgery up to 3 months post surgery

  15. Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy

    Carcinoembryonic Antigen (CEA) levels will be measured in blood samples and their predictive value for response to artesunate therapy. he predictive value will be evaluated by correlating CEA with pathological tumour regression grade and recurrence-free survival. Unit of Measure: Change in serum CEA levels (ng/mL)

    Time frame: Day 1 of study intervention (baseline assessment).

  16. Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy

    Carcinoembryonic Antigen (CEA) levels will be measured in blood samples and their predictive value for response to artesunate therapy. he predictive value will be evaluated by correlating CEA with pathological tumour regression grade and recurrence-free survival. Unit of Measure: Change in serum CEA levels (ng/mL)

    Time frame: Assessment at Day 7 of study intervention

  17. Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy

    Carcinoembryonic Antigen (CEA) levels will be measured in blood samples and their predictive value for response to artesunate therapy. he predictive value will be evaluated by correlating CEA with pathological tumour regression grade and recurrence-free survival. Unit of Measure: Change in serum CEA levels (ng/mL)

    Time frame: Assessment at Day 14 of study intervention

  18. Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy

    Carcinoembryonic Antigen (CEA) levels will be measured in blood samples and their predictive value for response to artesunate therapy. he predictive value will be evaluated by correlating CEA with pathological tumour regression grade and recurrence-free survival. Unit of Measure: Change in serum CEA levels (ng/mL)

    Time frame: Assessment at Day 42 of study intervention

  19. Immunohistochemical analyses of paraffin-embedded tumour sections to assess Kirsten rat sarcoma viral oncogene homolog (Kras) mutation status

    KRAS mutation status will be assessed in tumour tissue sections obtained from pre-intervention (diagnostic biopsy, Day 0) and post-intervention (surgical resection, Day 15) samples. Immunohistochemistry (IHC) will be performed. Comparisons will be made to evaluate changes in mutation status and association with response to artesunate therapy. Unit of Measure: Number and proportion (%) of participants with KRAS mutant tumours at each time point.

    Time frame: Pre and post intervention tumour samples from patients (Day 0 and Day 15)

  20. Immunohistochemical analyses of paraffin-embedded tumour sections to assess Mismatch Repair (MMR) status

    Mismatch Repair (MMR) status will be assessed in tumour tissue sections obtained from pre-intervention (diagnostic biopsy, Day 0) and post-intervention (surgical resection, Day 15) samples. Immunohistochemistry (IHC) will be performed. Unit of Measure: Number and proportion (%) of participants with MMR-deficient tumours at each time p

    Time frame: Pre and post intervention tumour samples from patients (Day 0 and Day 15)

  21. Immunohistochemical analyses of paraffin-embedded tumour for v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation status

    Number of patients with BRAF mutant tumours

    Time frame: Pre and post intervention tumour samples from patients (Day 0 and Day 15)

  22. Immunohistochemical analyses of paraffin-embedded tumour for Platelet derived growth factor (PDGF) expression

    Number of patients whose tumours show PDGF upregulation/downregulation following treatment intervention

    Time frame: Pre and post intervention tumour samples from patients (Day 0 and Day 15)

  23. Immunohistochemical analyses of paraffin-embedded tumour for Vascular endothelial Growth Factor (VEGF) expression

    Number of patients whose tumours show VEGF upregulation/downregulation following study intervention

    Time frame: Pre and post intervention tumour samples from patients (Day 0 and Day 15)

  24. Immunohistochemical analyses of paraffin-embedded tumour on Vascular endothelial Growth Factor Receptor (VEGFR) expression

    Number of patients whose tumours show VEGFR upregulation/downregulation following study intervention

    Time frame: Pre and post intervention tumour samples from patients (Day 0 and Day 15)

  25. Determination of proliferative activity (Ki-67 staining, Cluster of Differentiation 31 protein (CD31) staining)

    Number of patients whose tumours show an increase or reduction in proliferation markers Ki67 and CD31 following study intervention

    Time frame: Pre and post intervention tumour samples from patients (Day 0 and Day 15)

  26. Determination of activation of the Deoxyribonucleic acid damage response (DDR) pathway

    Number of patients whose tumour samples show activation of the DDR pathway following study intervention

    Time frame: Pre and post intervention tumour samples from patients (Day 0 and Day 15)

  27. Wnt/β-catenin proliferation pathway protein expression (e.g. c-myc and cyclinD1 proteins)

    Number of patients who show an increase or a decrease in expression of proteins involved in the Wnt/β-catenin proliferation pathway (e.g. c-myc and cyclinD1 proteins) following study intervention

    Time frame: Pre and post intervention tumour samples from patients (Day 0 and Day 15)

07

Study locations

6 sites
08

References and documents

Publications

  • Krishna S, Ganapathi S, Ster IC, Saeed ME, Cowan M, Finlayson C, Kovacsevics H, Jansen H, Kremsner PG, Efferth T, Kumar D. A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer. EBioMedicine. 2014 Nov 15;2(1):82-90. doi: 10.1016/j.ebiom.2014.11.010. eCollection 2015 Jan. PubMed 26137537 ↗
  • Kremsner PG, Krishna S. Antimalarial combinations. Lancet. 2004 Jul 17-23;364(9430):285-94. doi: 10.1016/S0140-6736(04)16680-4. PubMed 15262108 ↗
  • Krishna S, Bustamante L, Haynes RK, Staines HM. Artemisinins: their growing importance in medicine. Trends Pharmacol Sci. 2008 Oct;29(10):520-7. doi: 10.1016/j.tips.2008.07.004. Epub 2008 Aug 25. PubMed 18752857 ↗
  • Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics. 1983 Jun;39(2):499-503. PubMed 6354290 ↗
  • Singh NP, Panwar VK. Case report of a pituitary macroadenoma treated with artemether. Integr Cancer Ther. 2006 Dec;5(4):391-4. doi: 10.1177/1534735406295311. PubMed 17101767 ↗
  • Steinbruck L, Pereira G, Efferth T. Effects of artesunate on cytokinesis and G(2)/M cell cycle progression of tumour cells and budding yeast. Cancer Genomics Proteomics. 2010 Nov-Dec;7(6):337-46. PubMed 21156967 ↗
  • Reichert S, Reinboldt V, Hehlgans S, Efferth T, Rodel C, Rodel F. A radiosensitizing effect of artesunate in glioblastoma cells is associated with a diminished expression of the inhibitor of apoptosis protein survivin. Radiother Oncol. 2012 Jun;103(3):394-401. doi: 10.1016/j.radonc.2012.03.018. Epub 2012 May 3. PubMed 22560712 ↗
  • Nakase I, Lai H, Singh NP, Sasaki T. Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. Int J Pharm. 2008 Apr 16;354(1-2):28-33. doi: 10.1016/j.ijpharm.2007.09.003. Epub 2007 Sep 6. PubMed 17942255 ↗
  • Kim SJ., Kim MS., Lee JW., Lee CH., Yoo, H., Shin, SH., et al. Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro. J Cancer Res Clin Oncol. 2006;132 :129-135. Krishna K., Ganapathi S., Ster IS., Saeed MEM., Cowan M., Finlayson C., Kovacsevics H., Jansen H., Kremsner PG., Efferth T., Kumar D. A Randomised, Double Blind,Placebo Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer. EBioMedicine 2015;2(1) :82-90 Kreeftmeijer-Vegter, A. R., P. J. van Genderen., Visser LG., Bierman WF., Clerinx J., van Veldhuizen CK., de Vries PJ. "Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium." Malar J.2012;11:102. Lai H., Nakase I., Lacoste E., Singh NP., Sasaki. Artemisinin-transferrin conjugate retards growth of breast tumors in the rat. Anticancer Res 2009;29 :3807-3810.
  • Ho WE, Peh HY, Chan TK, Wong WS. Artemisinins: pharmacological actions beyond anti-malarial. Pharmacol Ther. 2014 Apr;142(1):126-39. doi: 10.1016/j.pharmthera.2013.12.001. Epub 2013 Dec 6. PubMed 24316259 ↗
  • Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012 Nov;13(11):1152-60. doi: 10.1016/S1470-2045(12)70348-0. Epub 2012 Sep 25. PubMed 23017669 ↗
  • Finlay IG, Meek D, Brunton F, McArdle CS. Growth rate of hepatic metastases in colorectal carcinoma. Br J Surg. 1988 Jul;75(7):641-4. doi: 10.1002/bjs.1800750707. PubMed 3416116 ↗
  • Ericsson T, Blank A, von Hagens C, Ashton M, Abelo A. Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. Eur J Clin Pharmacol. 2014 Dec;70(12):1453-63. doi: 10.1007/s00228-014-1754-2. Epub 2014 Sep 25. PubMed 25248945 ↗
  • Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol. 2001 Apr;18(4):767-73. doi: 10.3892/ijo.18.4.767. PubMed 11251172 ↗
  • Du JH, Zhang HD, Ma ZJ, Ji KM. Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother Pharmacol. 2010 Apr;65(5):895-902. doi: 10.1007/s00280-009-1095-5. Epub 2009 Aug 19. PubMed 19690861 ↗
  • Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, Baur A, Schuler G. Artesunate in the treatment of metastatic uveal melanoma--first experiences. Oncol Rep. 2005 Dec;14(6):1599-603. PubMed 16273263 ↗
  • Berdelle N, Nikolova T, Quiros S, Efferth T, Kaina B. Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells. Mol Cancer Ther. 2011 Dec;10(12):2224-33. doi: 10.1158/1535-7163.MCT-11-0534. Epub 2011 Oct 13. PubMed 21998290 ↗
  • Beccafico S, Morozzi G, Marchetti MC, Riccardi C, Sidoni A, Donato R, Sorci G. Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells. Carcinogenesis. 2015 Sep;36(9):1071-83. doi: 10.1093/carcin/bgv098. Epub 2015 Jul 7. PubMed 26153023 ↗
  • Anfosso L, Efferth T, Albini A, Pfeffer U. Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics J. 2006 Jul-Aug;6(4):269-78. doi: 10.1038/sj.tpj.6500371. Epub 2006 Jan 24. PubMed 16432535 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Aug 2032, 84 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Jul 31, 2025
StartEst.
Aug 15, 2025
Primary completionEst.
Aug 30, 2032
CompletionEst.
Jul 31, 2033
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07095309
Lead sponsor
Metanoic Health Ltd.
Collaborators
Clinical Research Malaysia
Responsible party
Sponsor
First posted
Jul 31, 2025
Start date
Aug 15, 2025 (estimated)
Primary completion
Aug 30, 2032 (estimated)
Completion
Jul 31, 2033 (estimated)
Last update
Jul 31, 2025

Study contacts

Dr Yolanda Augustin
Contact
yagustin@cadt.org.uk
+442087250446
Dr Nafeesa Mat Ali
Contact
nmatali@cadt.org.uk
Emeritus Professor Sanjeev Krishna, FRCP, ScD, FMedSci
study chair · Centre for Affordable Diagnotics and Therapeutics
Dr Yolanda Augustin
principal investigator · Centre for Affordable Diagnotics and Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Artesunate

Start the discussion